Cargando…

Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer

BACKGROUND: Circulating tumor cells (CTCs) represent a collection of heterogeneous cells. Studies have shown epithelial CTCs and folate receptor (FR) positive CTCs could be used as diagnostic biomarkers for lung cancer (LC). This study aimed to determine whether cell surface vimentin (CSV) positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiaohong, Wang, Liqiang, Wang, Xinni, Fan, Wan-Hung, Qin, Yinyin, Lin, Xinqing, Xie, Zhanhong, Liu, Ming, Ouyang, Ming, Li, Shiyue, Zhou, Chengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162210/
https://www.ncbi.nlm.nih.gov/pubmed/34055642
http://dx.doi.org/10.3389/fonc.2021.672687
_version_ 1783700663165779968
author Xie, Xiaohong
Wang, Liqiang
Wang, Xinni
Fan, Wan-Hung
Qin, Yinyin
Lin, Xinqing
Xie, Zhanhong
Liu, Ming
Ouyang, Ming
Li, Shiyue
Zhou, Chengzhi
author_facet Xie, Xiaohong
Wang, Liqiang
Wang, Xinni
Fan, Wan-Hung
Qin, Yinyin
Lin, Xinqing
Xie, Zhanhong
Liu, Ming
Ouyang, Ming
Li, Shiyue
Zhou, Chengzhi
author_sort Xie, Xiaohong
collection PubMed
description BACKGROUND: Circulating tumor cells (CTCs) represent a collection of heterogeneous cells. Studies have shown epithelial CTCs and folate receptor (FR) positive CTCs could be used as diagnostic biomarkers for lung cancer (LC). This study aimed to determine whether cell surface vimentin (CSV) positive CTCs could be used as a biomarker for LC as well. METHODS: 78 treatment-naïve non-small-cell lung cancer (NSCLC) patients, 21 patients with benign lung diseases (BLD) and 9 healthy donors (HD) were enrolled in this study. CTC detection was performed using CytoSorter(®) mesenchymal CTC kit (CSV). The correlation between CSV positive CTCs (CSV-CTCs) and LC patients’ clinicopathological characteristics would be evaluated, and diagnostic performances of CSV-CTCs and serum tumor markers for LC would be compared. RESULTS: CTC detection rates (average CTC count: range) in LC patients, patients with BLD and HD were 83.33% (2.47: 0-8), 47.62% (0.5: 0-3) and 0% (0: 0), respectively. CSV-CTCs could be used to differentiate LC patients from the patients with BLD and HD (P < 0.0001). CSV-CTCs were correlated with cancer stage, lymph node involvement and distant metastasis (P = 0.0062, 0.0014 and 0.0021, respectively). With a CTC cut-off value of 2, CSV-CTCs would have a sensitivity and specificity of 0.67 and 0.87, respectively, for diagnosing LC. CSV-CTC positive rates showed statistical differences among HD, BLD patients and LC patients at different cancer stages (P < 0.0001). Furthermore, CSV-CTC positive rates were positively correlated with tumor size, lymph node involvement and distant metastasis (P = 0.0163, 0.0196 and 0.03, respectively). CSV-CTCs had a better diagnostic performance than serum tumor makers, such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cancer antigen 125 (CA125) and CA153. CONCLUSION: When CTC cut-off is set to 2 CTCs per 7.5 mL of blood, CSV-CTCs can be considered as an acceptable biomarker for diagnosing LC with a sensitivity and specificity of 0.67 and 0.87, respectively.
format Online
Article
Text
id pubmed-8162210
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81622102021-05-29 Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer Xie, Xiaohong Wang, Liqiang Wang, Xinni Fan, Wan-Hung Qin, Yinyin Lin, Xinqing Xie, Zhanhong Liu, Ming Ouyang, Ming Li, Shiyue Zhou, Chengzhi Front Oncol Oncology BACKGROUND: Circulating tumor cells (CTCs) represent a collection of heterogeneous cells. Studies have shown epithelial CTCs and folate receptor (FR) positive CTCs could be used as diagnostic biomarkers for lung cancer (LC). This study aimed to determine whether cell surface vimentin (CSV) positive CTCs could be used as a biomarker for LC as well. METHODS: 78 treatment-naïve non-small-cell lung cancer (NSCLC) patients, 21 patients with benign lung diseases (BLD) and 9 healthy donors (HD) were enrolled in this study. CTC detection was performed using CytoSorter(®) mesenchymal CTC kit (CSV). The correlation between CSV positive CTCs (CSV-CTCs) and LC patients’ clinicopathological characteristics would be evaluated, and diagnostic performances of CSV-CTCs and serum tumor markers for LC would be compared. RESULTS: CTC detection rates (average CTC count: range) in LC patients, patients with BLD and HD were 83.33% (2.47: 0-8), 47.62% (0.5: 0-3) and 0% (0: 0), respectively. CSV-CTCs could be used to differentiate LC patients from the patients with BLD and HD (P < 0.0001). CSV-CTCs were correlated with cancer stage, lymph node involvement and distant metastasis (P = 0.0062, 0.0014 and 0.0021, respectively). With a CTC cut-off value of 2, CSV-CTCs would have a sensitivity and specificity of 0.67 and 0.87, respectively, for diagnosing LC. CSV-CTC positive rates showed statistical differences among HD, BLD patients and LC patients at different cancer stages (P < 0.0001). Furthermore, CSV-CTC positive rates were positively correlated with tumor size, lymph node involvement and distant metastasis (P = 0.0163, 0.0196 and 0.03, respectively). CSV-CTCs had a better diagnostic performance than serum tumor makers, such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cancer antigen 125 (CA125) and CA153. CONCLUSION: When CTC cut-off is set to 2 CTCs per 7.5 mL of blood, CSV-CTCs can be considered as an acceptable biomarker for diagnosing LC with a sensitivity and specificity of 0.67 and 0.87, respectively. Frontiers Media S.A. 2021-05-14 /pmc/articles/PMC8162210/ /pubmed/34055642 http://dx.doi.org/10.3389/fonc.2021.672687 Text en Copyright © 2021 Xie, Wang, Wang, Fan, Qin, Lin, Xie, Liu, Ouyang, Li and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xie, Xiaohong
Wang, Liqiang
Wang, Xinni
Fan, Wan-Hung
Qin, Yinyin
Lin, Xinqing
Xie, Zhanhong
Liu, Ming
Ouyang, Ming
Li, Shiyue
Zhou, Chengzhi
Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
title Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
title_full Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
title_fullStr Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
title_full_unstemmed Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
title_short Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
title_sort evaluation of cell surface vimentin positive circulating tumor cells as a diagnostic biomarker for lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162210/
https://www.ncbi.nlm.nih.gov/pubmed/34055642
http://dx.doi.org/10.3389/fonc.2021.672687
work_keys_str_mv AT xiexiaohong evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer
AT wangliqiang evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer
AT wangxinni evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer
AT fanwanhung evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer
AT qinyinyin evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer
AT linxinqing evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer
AT xiezhanhong evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer
AT liuming evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer
AT ouyangming evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer
AT lishiyue evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer
AT zhouchengzhi evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer